SMS Lifesciences India Limited — Important, 24-01-2025: Disclosure of material issue

The US FDA recently inspected Mahi Drugs Private Limited, a material subsidiary of SMS Lifesciences, at its API manufacturing facility in Vishakhapatnam. The inspection, which took place from January 20 to January 24, 2025, concluded with no observations noted. This positive outcome reflects well on the subsidiary's compliance and operational standards, potentially bolstering its reputation in the pharmaceutical sector. Investors should view this as a positive development, enhancing the company’s credibility in the US market and supporting future growth opportunities. Watch closely for any strategic impacts arising from this successful inspection.